日本癌症疫苗市場評估：依類型、技術、適應症、最終用戶、地區、機會和預測（2018-2032年）

日本癌症疫苗市場預計將從2024年的10.5億美元成長到2032年的16.8億美元，在2025-2032年的預測期內年複合成長率為 6%。由於預防和治療癌症的需求不斷增加，市場迅速擴大。疫苗對於降低癌症發生率和死亡率非常重要。市場成長的動力來自於癌症患者數量的增加、政府強有力的疫苗接種計劃以及公眾意識的提高。 mRNA疫苗、重組疫苗等疫苗技術的進步加速其研發和生產。製藥和生物技術公司加大對研發的投資，推動愛滋病毒和癌症等疾病的創新疫苗的開發。此外，政府機構，特別是發展中國家的政府機構積極資助和支持大規模的疫苗接種運動。大型生技公司齊心協力，共同創造大事。例如，Astellas Pharma Inc.宣布，其抗CLDN18.2單株抗體Vyloy（zolbetuximab）已獲得日本厚生勞動省批准，用於治療CLDN18.2陽性的不可切除的晚期復發性胃癌患者。 Vyloy 是全球第一個也是唯一一個獲得監管機構批准的CLDN18.2 標靶療法。有利的監管政策和不斷上漲的醫療成本將進一步推動市場擴張。老年人口的成長、新興經濟體醫療基礎設施的發展以及全球疫苗接種覆蓋率的提高預計將維持市場長期成長。

本報告調查並分析日本癌症疫苗市場，提供市場規模及預測、市場動態以及主要公司狀況的資訊。

目錄

第1章 專案範圍與定義

第2章 研究方法

第3章 執行摘要

第4章 日本癌症疫苗市場展望（2018年度至2032年度）

• 市場規模分析及預測
  • 金額
  • 數量
• 市場佔有率分析與預測
  • 依類型
  • 依技術
  • 依適應症
  • 依最終用戶
  • 依地區
  • 市場佔有率分析（前5名及其他、價值）（2024 財政年度）
• 市場地圖分析（2024年度）
  • 依類型
  • 依技術
  • 依適應症
  • 依最終用戶
  • 依地區

第5章 供需分析

第6章 價值鏈分析

第7章 波特五力分析

第8章 PESTLE 分析

第9章 定價分析

第10章 市場動態

• 市場驅動因素
• 市場挑戰

第11章 市場趨勢與發展

第12章 監理架構與創新

• 臨床試驗
• 監理機關核准

第13章 專利格局

第14章 個案研究

第15章 競爭格局

• 五大市場領導者的競爭矩陣
• 五大公司的SWOT 分析
• 十大主要公司的現狀
  • Takeda Pharmaceutical Company Limited
  • Daiichi Sankyo Company Limited
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Chugai Pharmaceutical Co., Ltd.
  • Astellas Pharma Inc.
  • GlaxoSmithKline plc
  • Otsuka Holdings Co., Ltd.
  • Eisai Co., Ltd.
  • Shionogi & Co., Ltd.

第16章 策略建議

第17章 關於調查公司/免責聲明

Japan cancer vaccines market is projected to witness a CAGR of 6% during the forecast period FY2025-FY2032, growing from USD 1.05 billion in FY2024 to USD 1.68 billion in FY2032. Japan cancer vaccines market is expanding rapidly, driven by the increasing need to prevent cancer, and cure it. Vaccines are essential for reducing morbidity and mortality from cancer. The market's growth is fueled by rising cases of cancer, strong government immunization programs, and increasing public awareness. Advancements in vaccine technology, such as mRNA and recombinant vaccines, are accelerating development and production. Increased R&D investments from pharmaceutical companies and biotech firms are leading to innovative vaccines for diseases such as HIV and cancer. Additionally, government organizations are actively funding and supporting large-scale vaccination campaigns, especially in developing countries. Biotechnology giants are coming together to be able to produce big results. For example, Astellas Pharma Inc., announced that Japan's Ministry of Health, Labor and Welfare (MHLW) approved Vyloy (zolbetuximab), an anti-CLDN18.2 monoclonal antibody to treat patients with CLDN18.2 positive, unresectable, advanced or recurrent gastric cancer. Vyloy is the first and only CLDN18.2-targeted therapy approved by any regulatory agency worldwide. Favorable regulatory policies and growing healthcare expenditures further support market expansion. The increasing geriatric population, rising healthcare infrastructure in emerging economies, and expanding global vaccination coverage are expected to sustain the market's long-term growth.

Research Breakthroughs Boosting Market Growth

One of the key factors propelling the Japan cancer vaccines market is research advancements. Innovative cancer vaccine research has been made possible by ongoing developments in immunotherapy, personalized medicine, and biotechnology. Japan has a solid background in medical research, with esteemed organizations and colleges focusing on the development of cancer vaccines. Novel antigens discovered as a result of advances in cancer immunology have made it possible to create vaccinations that specifically target and kill cancer cells. The development of innovative technologies has transformed the prevention and treatment of cancer, including mRNA and gene-based vaccinations. It is anticipated that these developments will treat different kinds of cancer, propelling market expansion. With Japan's focus on precision medicine and immuno-oncology, the country continues to make progress in understanding the molecular mechanisms of cancer, which is crucial for creating effective vaccines and therapies. For instance, NEC Bio B.V. presented interim results from a Phase 1 clinical trial of NECVAX-NEO1, an AI-driven personalized oral cancer vaccine in December 2024. The trial demonstrated the vaccine's safety and immunogenicity in patients with solid tumors, marking a significant advancement in personalized cancer immunotherapy.

Government Initiatives Fueling the Market Growth

In Japan, government measures have been instrumental in the expansion of the market for cancer vaccines. The Japanese government has continuously backed cancer research, contributing money to the creation of novel cancer treatments and vaccinations. The Ministry of Health, Labour, and Welfare (MHLW) in Japan has put more emphasis on cancer prevention in recent years, implementing public health initiatives and regulations to encourage early detection and immunization. In keeping with its goal of lowering cancer rates through immunization, the government has also started endorsing the HPV vaccine for the prevention of cervical cancer. A favorable environment for the development of cancer vaccines has also been created by Japan's significant investments in biotechnology and healthcare infrastructure. The government's commitment to reducing the cancer burden through innovation and healthcare reform is expected to drive the market's growth and accelerate the approval of new cancer vaccines. In September 2024, Japan, alongside the United States, Australia, and India, launched the Quad Cancer Moonshot Initiative. This collaborative effort seeks to reduce the cancer burden in the Indo-Pacific region by enhancing health infrastructure, expanding research, and improving access to cancer care.

Collaborative Environment Fueling the Market Growth

The market for cancer vaccines in Japan is expanding at a rapid pace due to growing alliances and partnerships between government agencies, academic institutions, and pharmaceutical businesses. The development of cancer vaccines is progressing more quickly due to partnerships between international and local actors that promote the sharing of resources, technology, and expertise. Japanese pharmaceutical giants like Takeda Pharmaceutical and Daiichi Sankyo are collaborating with foreign biotech companies and academic institutions to create innovative cancer vaccines. These collaborations lower the financial risk involved in developing a cancer vaccine while simultaneously enhancing access to cutting-edge technologies. Collaboration in clinical studies, regulatory approvals, and manufacturing procedures also guarantees that vaccines can be created effectively and get to market more quickly. The trend of collaboration enhances research, optimizes clinical testing, and brings diverse perspectives to the table, fueling innovation in cancer vaccines.

For instance, the Kawasaki Innovation Center for NanoMedicine (iCONM; Director: Kazunori Kataoka; Location: Kawasaki, Japan) have announced in collaboration with Tokyo Medical and Dental University, and Kyorin University that a group led by Prof. Satoshi Uchida, Principal Research Scientist of iCONM, has created a novel mRNA derivative and shown its high cellular immunity inducing anti-cancer activities in mice model. In tests employing melanoma and lymphoma model mice, this new mRNA exhibits strong anti-tumor effects, stimulates immune cells, and has double-stranded RNA in the form of comb teeth.

Future Market Scenario (FY2025 - FY2032F)

One of the main factors contributing to the anticipated growth of the cancer vaccines market is the increasing demand for treatment options to ensure patient safety by delivering the right quality of drug or any other such chemical product. The rising population and cases of cancer are also factors that will always propel the market's growth in the future. Given that technology is advancing, we can expect cutting-edge technology in the area. Players in this market are expanding at an unparalleled rate, introducing cost-effective and efficient technologies.

Key Players Landscape and Outlook

The key players in the market are significantly investing in the development of cancer vaccines and are utilizing strategies such as mergers, acquisitions, partnerships, and new product launches to improve their services and competitiveness. Such efforts will propel significant growth in the market, allowing large-cap industry players to increase their presence and, therefore, find new opportunities in this market.

For instance, the Japan Patent Office has sent Cleveland Clinic, a partner of Anixa Biosciences, Inc., a "Decision to Grant" notice for the patent application "Vaccine Adjuvants and Formulations." This new Japanese patent extends the claims for this novel breast cancer vaccine technology to an additional geographic region, beyond the U.S. and European patents previously awarded, as explained by Dr. Amit Kumar, Chairman and CEO of Anixa, in a July 17, 2024, press release.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Executive Summary

4. Japan Cancer Vaccines Market Outlook, FY2018-FY2032F

• 4.1. Market Size Analysis & Forecast
  • 4.1.1. By Value
  • 4.1.2. By Volume
• 4.2. Market Share Analysis & Forecast
  • 4.2.1. By Type
    • 4.2.1.1. Preventive Vaccines
    • 4.2.1.2. Therapeutic Vaccines
  • 4.2.2. By Technology
    • 4.2.2.1. Peptide-based vaccines
    • 4.2.2.2. Vector-based vaccines
    • 4.2.2.3. DNA/RNA-based vaccines
    • 4.2.2.4. Others
  • 4.2.3. By Indication
    • 4.2.3.1. Breast Cancer
    • 4.2.3.2. Lung Cancer
    • 4.2.3.3. Prostate Cancer
    • 4.2.3.4. Ovarian Cancer
    • 4.2.3.5. Others
  • 4.2.4. By End-user
    • 4.2.4.1. Hospitals
    • 4.2.4.2. Specialty Centers
    • 4.2.4.3. Cancer Research Institutes
    • 4.2.4.4. Others
  • 4.2.5. By Region
    • 4.2.5.1. North [Hokkaido and Tohoku]
    • 4.2.5.2. Central [Kanto and Chubu]
    • 4.2.5.3. South [Kansai, Chugoku, Shikoku, and Kyushu & Okinawa]
  • 4.2.6. By Company Market Share Analysis (Top 5 Companies and Others - By Value, FY2024)
• 4.3. Market Map Analysis, FY2024
  • 4.3.1. By Type
  • 4.3.2. By Technology
  • 4.3.3. By Indication
  • 4.3.4. By End-user
  • 4.3.5. By Region

5. Demand Supply Analysis

6. Value Chain Analysis

7. Porter's Five Forces Analysis

8. PESTLE Analysis

9. Pricing Analysis

10. Market Dynamics

• 10.1. Market Drivers
• 10.2. Market Challenges

11. Market Trends and Developments

12. Regulatory Framework and Innovation

• 12.1. Clinical Trials
• 12.2. Regulatory Approvals

13. Patent Landscape

14. Case Studies

15. Competitive Landscape

• 15.1. Competition Matrix of Top 5 Market Leaders
• 15.2. SWOT Analysis for Top 5 Players
• 15.3. Key Players Landscape for Top 10 Market Players
  • 15.3.1. Takeda Pharmaceutical Company Limited
    • 15.3.1.1. Company Details
    • 15.3.1.2. Key Management Personnel
    • 15.3.1.3. Products and Services
    • 15.3.1.4. Financials (As Reported)
    • 15.3.1.5. Key Market Focus and Geographical Presence
    • 15.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
  • 15.3.2. Daiichi Sankyo Company Limited
  • 15.3.3. Merck & Co., Inc.
  • 15.3.4. Moderna, Inc.
  • 15.3.5. Chugai Pharmaceutical Co., Ltd.
  • 15.3.6. Astellas Pharma Inc.
  • 15.3.7. GlaxoSmithKline plc
  • 15.3.8. Otsuka Holdings Co., Ltd.
  • 15.3.9. Eisai Co., Ltd.
  • 15.3.10. Shionogi & Co., Ltd.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

16. Strategic Recommendations

17. About Us and Disclaimer

List of Tables

• Table 1. Competition Matrix of Top 5 Market Leaders
• Table 2. Mergers & Acquisitions/ Joint Ventures (If Applicable)
• Table 3. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

• Figure 1. Japan Cancer Vaccines Market, By Value, In USD Billion, FY2018-FY2032F
• Figure 2. Japan Cancer Vaccines Market, By Volume, In Million Units, FY2018-FY2032F
• Figure 3. Japan Cancer Vaccines Market Share (%), By Type, FY2018-FY2032F
• Figure 4. Japan Cancer Vaccines Market Share (%), By Technology, FY2018-FY2032F
• Figure 5. Japan Cancer Vaccines Market Share (%), By Indication, FY2018-FY2032F
• Figure 6. Japan Cancer Vaccines Market Share (%), By End-user, FY2018-FY2032F
• Figure 7. Japan Cancer Vaccines Market Share (%), By Region, FY2018-FY2032F
• Figure 8. By Type Map-Market Size (USD Billion) & Growth Rate (%), FY2024
• Figure 9. By Technology Map-Market Size (USD Billion) & Growth Rate (%), FY2024
• Figure 10. By Indication Map-Market Size (USD Billion) & Growth Rate (%), FY2024
• Figure 11. By End-user Map-Market Size (USD Billion) & Growth Rate (%), FY2024
• Figure 12. By Region Map-Market Size (USD Billion) & Growth Rate (%), FY2024